Hinna Hamid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hinna Hamid has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Mohammad Sarwar Alam
Department of Chemistry, New Delhi, India
12 shared publicationsAbhijeet Dhulap
CSIR Unit for Research and Development of Information Products, Pune 411038, India
11 shared publicationsMushtaq A. Tantray
Chemistry Research Lab Department of Chemistry Govt. Degree College Baramulla J&K 193103 India
10 shared publicationsImran Khan
Department of Chemistry, Faculty of Science, Jamia Hamdard (Hamdard University), New Delhi 110062, India
9 shared publicationsAbul Kalam
Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi 110062, India
6 shared publications- Mohammad Sarwar Alam
Department of Chemistry, School of Chemical and Life Sciences, New Delhi, India
6 shared publications
Latest Publications
- 6 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (10) , 1-24
The design and synthesis of cysteine protease inhibitors containing isoxazole bearing warheads against Leishmania donovani
Cysteine proteases are critical drug targets for Trypanosomatids, crucial for the host cell invasion, survival and establishing infection. The current therapeutic regimen for leishmaniasis is inadequate, necessitating the search for safer anti-leishmanial agents. A fourteen-member library of new isoxazole derivatives was synthesised using a 1, 3-dipolar cycloaddition approach and then evaluated for antileishmanial activity. Ligands PB, PM and PE were found most effective against intramacrophage amastigotes of Leishmania donovani with EC50 values of 2.42μM, 2.93 μM and 5.19μM, respectively, compared to Amphotericin-B (IC50 2.15 μM). They also inhibited the promastigote stage of the parasite with an EC50 of 9.44 µM, 11.99µM and 14.81 µM, respectively. Mechanistic in silico studies against cysteine protease, followed by in vitro corroboration using Bz-Arg-AMC hydrochloride fluorogenic peptide substrate ascertained the promising potential of PM (IC50 10.34 μM) as a cysteine protease inhibitor. Compounds fared well in the toxicity screen against THP-1 human monocytic cells. Compounds PB, PM and PE emerged as potent hits, and PM with high activity and low toxicity can be further developed into a potent lead molecule (s) to fight Leishmania donovani. The design of isoxazole-based small molecule libraries presents a promising strategy for the development of safer and potent antileishmanial agents targeting cysteine proteases. Graphical Abstract The alternative text for this image may have been generated using AI.
- 6 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (10) , 1-24
The design and synthesis of cysteine protease inhibitors containing isoxazole bearing warheads against Leishmania donovani
Cysteine proteases are critical drug targets for Trypanosomatids, crucial for the host cell invasion, survival and establishing infection. The current therapeutic regimen for leishmaniasis is inadequate, necessitating the search for safer anti-leishmanial agents. A fourteen-member library of new isoxazole derivatives was synthesised using a 1, 3-dipolar cycloaddition approach and then evaluated for antileishmanial activity. Ligands PB, PM and PE were found most effective against intramacrophage amastigotes of Leishmania donovani with EC50 values of 2.42μM, 2.93 μM and 5.19μM, respectively, compared to Amphotericin-B (IC50 2.15 μM). They also inhibited the promastigote stage of the parasite with an EC50 of 9.44 µM, 11.99µM and 14.81 µM, respectively. Mechanistic in silico studies against cysteine protease, followed by in vitro corroboration using Bz-Arg-AMC hydrochloride fluorogenic peptide substrate ascertained the promising potential of PM (IC50 10.34 μM) as a cysteine protease inhibitor. Compounds fared well in the toxicity screen against THP-1 human monocytic cells. Compounds PB, PM and PE emerged as potent hits, and PM with high activity and low toxicity can be further developed into a potent lead molecule (s) to fight Leishmania donovani. The design of isoxazole-based small molecule libraries presents a promising strategy for the development of safer and potent antileishmanial agents targeting cysteine proteases. Graphical Abstract The alternative text for this image may have been generated using AI.
- 11 September 2025
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1350
Design and synthesis of novel benzimidazole-tethered benzodiazepinones as promising anti-melanoma agents targeting JAK-3
- 11 September 2025
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1350
Design and synthesis of novel benzimidazole-tethered benzodiazepinones as promising anti-melanoma agents targeting JAK-3
- 1 September 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (31) , 6900-6928
Design and Synthesis of Benzimidazole Carboxamide Cysteine Protease Inhibitors as Promising Anti-leishmanial Agents
Introduction: More than 20 protozoan species of Leishmania are responsible for causing Leishmaniasis, an infection spread by blood-feeding phlebotomine sandflies. A narrow pool of drugs is currently available rendering the current drug stratagem to treat this infection . Development of novel, less toxic, and more effective regimens is thus a need of the hour. Design and synthesis of benzo[d]imidazole carboxamides as agents to combat Leishmaniasis are also required. Methods: 14 benzo[d]imidazole carboxamides were synthesized and gauged against L. donovani promastigotes and intramacrophage amastigote forms. All of the tested compounds exhibited significant anti-promastigote properties with IC50 well below 10 uM. Compounds 4a, 4b, and 4d, showing the highest anti-parasitic activity against promastigote forms (IC50 0.91- 1.33 μM), were also found to be associated with better anti-leishmanial potential (IC50 0.78- 1.67 μM) against the intramacrophage amastigotes comparable to Amphotericin-B (0.13 μM), a drug used for Leishmaniasis. Compound (4a), namely N-(2-(trifluoromethyl)-1Hbenzo[ d]imidazol-5-yl)benzo[d][1,3]-5-carboxamide-dioxole, was found to be most potent against L. donovani amastigotes among all the tested compounds, and demonstrated better antileishmanial properties (IC50 0.78 μM) when compared to the standard. Compound 4a was also assessed for its toxicity profile against THP-1 human monocytic cells. To establish the molecular target(s) in silico, molecular docking studies were performed against cysteine protease, a putative virulence factor of Leishmania parasites, and nucleoside diphosphate kinase, an enzyme with a critical role in nucleotide recycling, also associated with resistance in Leishmania strains. Compound 4a showed better binding affinity than the standard to these targets; furthermore, the molecular dynamic simulation studies further affirmed the stability of compound 4a, within the active site of the targets. In vitro, cysteine protease inhibitory activity (IC50 8.53 μM) using Bz-Arg-AMC hydrochloride fluorogenic peptide substrate established the promising potential of 4a as a cysteine protease inhibitor. Results: Computational ADMET analysis indicated appropriate pharmacokinetic profile and physicochemical characteristics for all members of the synthesized library. Conclusion: Both in vitro and in silico studies indicate that the synthesized imidazole carboxamides can act as potent hits and that N-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5- yl)benzo[d][1,3]-5-carboxamide-dioxole 4a can be an effective hit molecule which can be further developed into potent lead molecule (s) to fight Leishmania donovani.
- 1 September 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (31) , 6900-6928
Design and Synthesis of Benzimidazole Carboxamide Cysteine Protease Inhibitors as Promising Anti-leishmanial Agents
Introduction: More than 20 protozoan species of Leishmania are responsible for causing Leishmaniasis, an infection spread by blood-feeding phlebotomine sandflies. A narrow pool of drugs is currently available rendering the current drug stratagem to treat this infection . Development of novel, less toxic, and more effective regimens is thus a need of the hour. Design and synthesis of benzo[d]imidazole carboxamides as agents to combat Leishmaniasis are also required. Methods: 14 benzo[d]imidazole carboxamides were synthesized and gauged against L. donovani promastigotes and intramacrophage amastigote forms. All of the tested compounds exhibited significant anti-promastigote properties with IC50 well below 10 uM. Compounds 4a, 4b, and 4d, showing the highest anti-parasitic activity against promastigote forms (IC50 0.91- 1.33 μM), were also found to be associated with better anti-leishmanial potential (IC50 0.78- 1.67 μM) against the intramacrophage amastigotes comparable to Amphotericin-B (0.13 μM), a drug used for Leishmaniasis. Compound (4a), namely N-(2-(trifluoromethyl)-1Hbenzo[ d]imidazol-5-yl)benzo[d][1,3]-5-carboxamide-dioxole, was found to be most potent against L. donovani amastigotes among all the tested compounds, and demonstrated better antileishmanial properties (IC50 0.78 μM) when compared to the standard. Compound 4a was also assessed for its toxicity profile against THP-1 human monocytic cells. To establish the molecular target(s) in silico, molecular docking studies were performed against cysteine protease, a putative virulence factor of Leishmania parasites, and nucleoside diphosphate kinase, an enzyme with a critical role in nucleotide recycling, also associated with resistance in Leishmania strains. Compound 4a showed better binding affinity than the standard to these targets; furthermore, the molecular dynamic simulation studies further affirmed the stability of compound 4a, within the active site of the targets. In vitro, cysteine protease inhibitory activity (IC50 8.53 μM) using Bz-Arg-AMC hydrochloride fluorogenic peptide substrate established the promising potential of 4a as a cysteine protease inhibitor. Results: Computational ADMET analysis indicated appropriate pharmacokinetic profile and physicochemical characteristics for all members of the synthesized library. Conclusion: Both in vitro and in silico studies indicate that the synthesized imidazole carboxamides can act as potent hits and that N-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5- yl)benzo[d][1,3]-5-carboxamide-dioxole 4a can be an effective hit molecule which can be further developed into potent lead molecule (s) to fight Leishmania donovani.
- 3 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (8) , 10667-10689
Synthesis and biological evaluation of thiourea-tethered benzodiazepinones as anti-proliferative agents targeting JAK-3 kinase
Owing to anti-cancer potency of the benzodiazepinone derivatives, the study aims to synthesize a library of thiourea-tethered benzodiazepinone derivatives targeting JAK-3 kinase for anti-breast cancer potency. Test compounds showed favourable in silico interactions with the active site of JAK-3 kinase. Compound 5i demonstrated a significant JAK-3 kinase inhibitory potential of 68.28% and appreciable growth inhibition (72.9%) of MDA-MB-468 (breast cancer cells) as per the anti-proliferative screening done by NCI-USA. In addition, 5i was also found to induce apoptosis moderately by 12.4% in the late apoptosis quadrant and arrested cell cycle at the G2/M phase. The wound healing assay demonstrated the anti-metastatic impact of drug 5i by reducing the migratory potential of MDA-MB-468 cells and was found to be stable within the target protein in the molecular dynamic simulation. All the synthesized compounds exhibited drug-appropriate pharmacokinetic profiles as corroborated by computational ADMET analysis. The study indicates that the synthesized library of benzodiazepinone derivatives is efficacious and compound 5i has emerged as a promising hit candidate, and can be explored further for development of potent JAK-3 kinase inhibitors targeting breast cancer. Graphical abstract
- 3 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (8) , 10667-10689
Synthesis and biological evaluation of thiourea-tethered benzodiazepinones as anti-proliferative agents targeting JAK-3 kinase
Owing to anti-cancer potency of the benzodiazepinone derivatives, the study aims to synthesize a library of thiourea-tethered benzodiazepinone derivatives targeting JAK-3 kinase for anti-breast cancer potency. Test compounds showed favourable in silico interactions with the active site of JAK-3 kinase. Compound 5i demonstrated a significant JAK-3 kinase inhibitory potential of 68.28% and appreciable growth inhibition (72.9%) of MDA-MB-468 (breast cancer cells) as per the anti-proliferative screening done by NCI-USA. In addition, 5i was also found to induce apoptosis moderately by 12.4% in the late apoptosis quadrant and arrested cell cycle at the G2/M phase. The wound healing assay demonstrated the anti-metastatic impact of drug 5i by reducing the migratory potential of MDA-MB-468 cells and was found to be stable within the target protein in the molecular dynamic simulation. All the synthesized compounds exhibited drug-appropriate pharmacokinetic profiles as corroborated by computational ADMET analysis. The study indicates that the synthesized library of benzodiazepinone derivatives is efficacious and compound 5i has emerged as a promising hit candidate, and can be explored further for development of potent JAK-3 kinase inhibitors targeting breast cancer. Graphical abstract
- 27 December 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (48)
Synthesis and Design of New 1,3,4‐Oxadiazole Benzimidazole Hybrids as Potential Antibacterial Agents Against MRSA by Targeting FabI
The current investigation describes the synthesis of the 1,3,4‐oxadiazole benzimidazole hybrids 5 (a–m) as antibacterial agents against methicillin‐resistant Staphylococcus aureus (MRSA) by targeting the enoyl‐acyl carrier protein binding site of enoyl‐acyl carrier protein reductase (FabI). Compounds having better (2–6 µg/mL) minimum inhibitory concentrations (MIC) than ampicillin (100 µg/mL) in initial screening using the broth dilution method against S. aureus ( ATCC ‐29213) were further gauged for their antimicrobial potential against MRSA (ATCC 4330) using sultamicillin as a standard. 5‐(2‐(4‐Chlorophenyl)‐1 H ‐benzo[d]imidazol‐6‐yl)‐ N ‐phenyl‐1,3,4‐oxadiazol‐2‐amine ( 5a ) was found to be most potent against MRSA with a MIC of 6 µg/mL in comparison to sultamicillin (25 µg/mL). Furthermore, the time‐kill assay exhibited that compound 5a was bactericidal and demonstrated a high safety profile, as hemolysis caused in human red blood cells was insignificant (1.6%) at the concentration of 6 µg/mL (MIC × 3). To establish the molecular target of action, in silico molecular docking studies were performed against Sa FabI to reconnoiter the intervention of the molecules in the FAS‐II pathway. Compound 5a exhibited high binding affinity (−11.19) to the target; furthermore, the molecular dynamic simulation studies affirmed the stability of compound 5a , within the active site of the target. All compounds exhibited drug‐appropriate physicochemical characteristics and pharmacokinetic profiles as established by computational ADMET analysis. The study revealed that the synthesized library of small‐molecule oxadiazole benzimidazole hybrids holds promise for developing new antibacterial agents against MRSA infections.
- 27 December 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (48)
Synthesis and Design of New 1,3,4‐Oxadiazole Benzimidazole Hybrids as Potential Antibacterial Agents Against MRSA by Targeting FabI
The current investigation describes the synthesis of the 1,3,4‐oxadiazole benzimidazole hybrids 5 (a–m) as antibacterial agents against methicillin‐resistant Staphylococcus aureus (MRSA) by targeting the enoyl‐acyl carrier protein binding site of enoyl‐acyl carrier protein reductase (FabI). Compounds having better (2–6 µg/mL) minimum inhibitory concentrations (MIC) than ampicillin (100 µg/mL) in initial screening using the broth dilution method against S. aureus ( ATCC ‐29213) were further gauged for their antimicrobial potential against MRSA (ATCC 4330) using sultamicillin as a standard. 5‐(2‐(4‐Chlorophenyl)‐1 H ‐benzo[d]imidazol‐6‐yl)‐ N ‐phenyl‐1,3,4‐oxadiazol‐2‐amine ( 5a ) was found to be most potent against MRSA with a MIC of 6 µg/mL in comparison to sultamicillin (25 µg/mL). Furthermore, the time‐kill assay exhibited that compound 5a was bactericidal and demonstrated a high safety profile, as hemolysis caused in human red blood cells was insignificant (1.6%) at the concentration of 6 µg/mL (MIC × 3). To establish the molecular target of action, in silico molecular docking studies were performed against Sa FabI to reconnoiter the intervention of the molecules in the FAS‐II pathway. Compound 5a exhibited high binding affinity (−11.19) to the target; furthermore, the molecular dynamic simulation studies affirmed the stability of compound 5a , within the active site of the target. All compounds exhibited drug‐appropriate physicochemical characteristics and pharmacokinetic profiles as established by computational ADMET analysis. The study revealed that the synthesized library of small‐molecule oxadiazole benzimidazole hybrids holds promise for developing new antibacterial agents against MRSA infections.
- 14 October 2022
- Published by Springer Nature in Waste and Biomass Valorization
- Vol. 14 (5) , 1625-1636
Development and Characterization of Chitosan and Beeswax–Chitosan Coated Biodegradable Corn Husk and Sugarcane Bagasse-Based Cellulose Paper
- 14 October 2022
- Published by Springer Nature in Waste and Biomass Valorization
- Vol. 14 (5) , 1625-1636
Development and Characterization of Chitosan and Beeswax–Chitosan Coated Biodegradable Corn Husk and Sugarcane Bagasse-Based Cellulose Paper
- Open Access
- 7 March 2022
- Published by Springer Nature in Research Square
Development and characterization of chitosan and beeswax coated biodegradable corn husk and sugarcane bagasse-based cellulose paper.
This research focuses on the development of paper from lignocellulosic agricultural wastes, viz., corn husk (CH), which is an underexplored material and sugarcane baggase (SB), in varying proportions, through soda pulping and enhancement of their functionalities through chitosan and chitosan-beeswax emulsion coatings. Fiber digestion conditions were as follows: 100°C (30 min); 100–162°C (90 min) and 162°C (90 min); followed by blowing, quenching and then refining of both treated CH and SB pulp to a Canadian Standard Freeness (CSF) of 400–450 mL. The handsheets of 80 GSM (grammage) were prepared as per the standard ISO-5269/1 and were tested for their mechanical and barrier properties as per standard methods of ISO. Handsheets developed from the blend of SB and CH (50:50) and SB fibers (100%) were found to have better mechanical strength (in terms of burst, tensile and tear strength) in comparison to CH fibers (100%). The effect of coatings on mechanical, water resistance, micro-structural, and biodegradable properties of the cellulose papers were also assessed. The chitosan coating significantly improved (p < 0.05) the mechanical properties of papers, the barrier properties against water vapor, moisture and air were also enhanced (up to 85%). Papers coated with beeswax–chitosan emulsion had the longest absorbency time, followed by chitosan-coated and uncoated papers. The results advocated for beeswax–chitosan emulsion as the best among the coatings tested, for aforementioned cellulose papers to enhance their barrier properties.
- 7 March 2022
- Published by Springer Nature in Research Square
Open AccessDevelopment and characterization of chitosan and beeswax coated biodegradable corn husk and sugarcane bagasse-based cellulose paper.
This research focuses on the development of paper from lignocellulosic agricultural wastes, viz., corn husk (CH), which is an underexplored material and sugarcane baggase (SB), in varying proportions, through soda pulping and enhancement of their functionalities through chitosan and chitosan-beeswax emulsion coatings. Fiber digestion conditions were as follows: 100°C (30 min); 100–162°C (90 min) and 162°C (90 min); followed by blowing, quenching and then refining of both treated CH and SB pulp to a Canadian Standard Freeness (CSF) of 400–450 mL. The handsheets of 80 GSM (grammage) were prepared as per the standard ISO-5269/1 and were tested for their mechanical and barrier properties as per standard methods of ISO. Handsheets developed from the blend of SB and CH (50:50) and SB fibers (100%) were found to have better mechanical strength (in terms of burst, tensile and tear strength) in comparison to CH fibers (100%). The effect of coatings on mechanical, water resistance, micro-structural, and biodegradable properties of the cellulose papers were also assessed. The chitosan coating significantly improved (p < 0.05) the mechanical properties of papers, the barrier properties against water vapor, moisture and air were also enhanced (up to 85%). Papers coated with beeswax–chitosan emulsion had the longest absorbency time, followed by chitosan-coated and uncoated papers. The results advocated for beeswax–chitosan emulsion as the best among the coatings tested, for aforementioned cellulose papers to enhance their barrier properties.
- 1 March 2022
- Published by Elsevier in Food Control
- Vol. 133
Assessing the consumer acceptance and storability of chitosan and beeswax coated cellulose packaging for whole wheat bread
- 1 March 2022
- Published by Elsevier in Food Control
- Vol. 133
Assessing the consumer acceptance and storability of chitosan and beeswax coated cellulose packaging for whole wheat bread
- 1 February 2022
- Published by Elsevier in Bioorganic Chemistry
- Vol. 119, 105512
Design, synthesis, in vitro antiproliferative evaluation and GSK-3β kinase inhibition of a new series of pyrimidin-4-one based amide conjugates
- 1 February 2022
- Published by Elsevier in Bioorganic Chemistry
- Vol. 119, 105512
Design, synthesis, in vitro antiproliferative evaluation and GSK-3β kinase inhibition of a new series of pyrimidin-4-one based amide conjugates
- 1 January 2021
- Published by Elsevier in Bioorganic Chemistry
- Vol. 106, 104458
In silico designing, in vitro and in vivo evaluation of potential PPAR-γ agonists derived from aryl propionic acid scaffold
- 1 January 2021
- Published by Elsevier in Bioorganic Chemistry
- Vol. 106, 104458
In silico designing, in vitro and in vivo evaluation of potential PPAR-γ agonists derived from aryl propionic acid scaffold